The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

However, neither DRC nor other African nations produce the vaccines that could slow the spread of mpox and eventually help it ...

The 24,000m² facility can reconfigure rapidly for the production of up to four different products simultaneously.

A French pharmaceutical company has been trying to stop a proposed condo development near its Toronto campus by arguing that ...

Adult Vaccine Market Adult Vaccine Market Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, ...

As updated coronavirus vaccines hit U.S. pharmacy shelves, adults without health insurance are discovering the shots are no longer free, instead costing up to $200. The federal Bridge Access ...

Pneumococcal Vaccine Market” from 2024-2034 with covered segments By Vaccine Type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Va ...

But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...